Granules India Limited (NSE: GRANULES)
India
· Delayed Price · Currency is INR
570.90
+14.45 (2.60%)
Feb 4, 2025, 3:30 PM IST
Granules India Revenue
Granules India had revenue of 11.38B INR in the quarter ending December 31, 2024, a decrease of -1.55%. This brings the company's revenue in the last twelve months to 44.60B, down -1.46% year-over-year. In the fiscal year ending March 31, 2024, Granules India had annual revenue of 45.06B, down -0.12%.
Revenue (ttm)
44.60B
Revenue Growth
-1.46%
P/S Ratio
n/a
Revenue / Employee
10.99M
Employees
4,057
Market Cap
138.42B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 45.06B | -55.50M | -0.12% |
Mar 31, 2023 | 45.12B | 7.47B | 19.84% |
Mar 31, 2022 | 37.65B | 5.27B | 16.29% |
Mar 31, 2021 | 32.38B | 6.39B | 24.59% |
Mar 31, 2020 | 25.99B | 3.19B | 14.02% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 516.03B |
Divi's Laboratories | 90.78B |
Cipla | 267.20B |
Mankind Pharma | 116.41B |
Zydus Lifesciences | 214.84B |
Apollo Hospitals Enterprise | 204.69B |
Aurobindo Pharma | 302.95B |
Alkem Laboratories | 128.32B |
Granules India News
- 5 days ago - Granules India gains FDA approval for generic Vyvanse capsules - Business Upturn
- 11 days ago - Granules India shares fall nearly 4% on Q3 results - Business Upturn
- 6 weeks ago - Granules India large trade: 1.3% equity worth Rs 191 crore changes hands - Business Upturn
- 7 weeks ago - Granules India receives USFDA approval for Lisdexamfetamine Dimesylate Chewable tablets - Business Upturn
- 2 months ago - Compliance issues at Granules India’s Gagillapur plant - The Times of India
- 2 months ago - Granules India says US FDA action may impact new product approvals, expect meet with FDA soon - Business Upturn
- 2 months ago - Granules India stock falls over 10% from day’s high as US FDA classifies inspection as “Official Action Indicated” - Business Upturn
- 2 months ago - Granules India’s Gagillapur facility receives OAI classification from US FDA - Business Upturn